[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100605514":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":24,"centralContacts":28,"locations":34,"responsibleParty":49,"collaborators":19,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":58,"sex":59,"minAge":60,"maxAge":19,"enrollmentInfo":61,"targetDuration":19,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":71,"overallStatus":75,"whyStopped":19,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"University Hospital, Tours","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"study group","This is the single arm of this study. Patients will provide at month 0, month 3 and month 6\n\n1. 1 sputum sample after administration of isotonic saline nebulization and\n2. 1 blood sample",[12,13],"Other: Blood sample","Other: sputum sample",[15,20],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"Blood sample","Each patient will have a 5-10 ml blood sample taken at M0, M3, and M6.",[9],null,{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":19},"sputum sample","Each patient will provide a sputum sample at M0, M3, and M6.",[9],[25],{"name":26,"affiliation":5,"role":27},"Marion FERREIRA, Dr","PRINCIPAL_INVESTIGATOR",[29],{"name":26,"role":30,"phone":31,"phoneExt":32,"email":33},"CONTACT","247471640","+33","marion.ferreira@chu-tours.fr",[35],{"facility":36,"status":19,"city":37,"state":19,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"university hospital, Tours","Tours","37044","France","FR",{"type":42,"coordinates":43},"Point",[44,45],0.70398,47.39484,{"lat":45,"lon":44},[48],{"name":26,"role":30,"phone":31,"phoneExt":32,"email":33},{"type":50,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100605514","immune-response-to-immunotherapy-in-lung-cancer-study-of-sputum-and-blood-samples-100605514",false,"NCT07163507","Immune Response to Immunotherapy in Lung Cancer: Study of Sputum and Blood Samples","RICEPS-2","Inclusion Criteria:\n\n. Age 18 years or older\n\n* Diagnosis of locally advanced or metastatic non-small cell lung cancer (NSCLC)\n* Requiring initiation of treatment with anti-PD1 or anti-PDL1 ICI (nivolumab, pembrolizumab, atezolizumab, durvalumab, cemiplimab), with or without chemotherapy\n* Never having received ICI treatment\n* Affiliated with a social security system\n* Having signed a written, free, and informed consent form\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women\n* Individuals under guardianship, conservatorship, or judicial protection, or in a situation of deprivation of liberty",true,"ALL","18 Years",{"count":62,"type":63},50,"ESTIMATED","INTERVENTIONAL",[66],"NA","Lung cancer is the leading cause of cancer-related death worldwide, with nearly 2.48 million cases and 1.8 million deaths in 2022. Despite therapeutic progress, late diagnosis and high mortality make it a major public health issue. Immune checkpoint inhibitors (ICI) such as nivolumab, pembrolizumab, and atezolizumab have improved outcomes for some patients, but only a small proportion benefit, and side effects can be severe. Research is focusing on combining ICIs with chemotherapy, radiotherapy, or other immunotherapies, but reliable biomarkers to predict responders are still lacking. The tumor microenvironment, which promotes resistance, is a promising therapeutic target. The RICEPS study (2021-2023) found specific immune cells and cytokines linked to treatment response, and the ongoing RICEPS-2 trial aims to confirm these findings in a larger group to better understand immune dynamics in lung cancer under ICI therapy.",[69,70],"Lung Cancer (NSCLC)","Lung Cancer (Non-Small Cell)",[72,73,74],"immunotherapy","sputum samples","blood samples","NOT_YET_RECRUITING","2026-03-17",{"date":78,"type":79},"2026-03-18","ACTUAL",{"date":81,"type":63},"2026-04",{"date":83,"type":63},"2028-10",{"name":5,"class":6},1]